Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.74 |
| ▸ | SIRT6 | Q8N6T7 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 6/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | TP53 | P04637 | 3/20 | 0.58 |
| ▸ | PKM | P14618 | 2/20 | 0.58 |
| ▸ | CASP3 | P42574 | 1/20 | 0.58 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.58 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.58 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.58 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.57 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.57 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16028728 | 0.83 | RAB9A (0.74) | RAB9AALDH1A1SIRT6MEN1KMT2A | |
| SCHEMBL16179518 | 0.79 | SIRT6 (1.00) | RAB9AALDH1A1SIRT6MEN1KMT2A | |
| SCHEMBL20522825 | 0.78 | NPC1 (0.73) | RAB9AMEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL1455278 | 0.77 | RAB9A (0.69) | RAB9AALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL6633899 | 0.77 | PTPN2 (0.75) | RAB9AALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL16179714 | 0.77 | MEN1 (1.00) | RAB9AALDH1A1SIRT6MEN1KMT2A | |
| SCHEMBL29564094 | 0.77 | MEN1 (1.00) | RAB9AALDH1A1SIRT6MEN1KMT2A | |
| SCHEMBL23011774 | 0.77 | ALDH1A1 (0.84) | RAB9AALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL6632563 | 0.77 | RAB9A (0.68) | RAB9AALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL16179844 | 0.76 | SIRT6 (1.00) | RAB9AALDH1A1SIRT6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9233961-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2016-01-12 | — | — | US | disclosed |
| US-9233961-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2016-01-12 | — | — | US | disclosed |
| US-9233961-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2016-01-12 | — | — | US | disclosed |
| WO-2014151630-A2 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014151630-A2 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2014-09-25 | — | — | WO | disclosed |
| US-20140275013-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275013-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275013-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275013-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | TYR, TBCA, MAPT | RAB9A 1346/4885ALDH1A1 816/4885SIRT6 2837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.